DocGo Inc

Análisis de la acción DocGo Inc (DCGO)

$0.247

+0.004 (+1.56%)Al cierre

Loading chart…
Máximo
0.250
Apertura
0.242
Precio medio ponderado por volumen
0.25
Volumen
335.39K
Capitalización
326.03M
Mínimo
0.241
Importe
82.55K
EV/EBITDA, TTM
-0.37

DocGo Inc. is a mobile healthcare services company that uses dispatch and communication technology to help provide mobile, in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations and healthcare transportation in major metropolitan cities in the United States and the United Kingdom. The Company’s offerings also include mobile phlebotomy lab services, which is engaged in addressing critical gaps in diagnostic care for underserved populations. The Mobile Health Services include a variety of healthcare services performed at homes, offices and other locations and event services, such as on-site healthcare support at sporting events and concerts. The Transportation Services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports.

www.docgo.com

Análisis de IA of DocGo Inc (DCGO)

Vender

DocGo Inc. is not a good buy right now. The current price is $0.2474, and the company has reported significant losses, with a net income loss of $15.82 million in Q2 2026, worsening from a $11.16 million loss last year. The RSI is at 41.90, indicating a lack of momentum for a potential upward trend. Additionally, the stock is down 72.14% year-to-date, reflecting ongoing financial struggles and market skepticism.

Métricas de valoración

El PER previsto actual de DocGo Inc (DCGO) es 60.24, frente a su media de 5 años de 31.07.

PER previsto

Sobrevalorado
Media 5A P/E
31.07
P/E actual
60.24
Sobrevalorada
58.50
Infravalorada
3.63

EV/EBITDA previsto

Valor razonable
Media 5A EV/EBITDA
802.88
EV/EBITDA actual
-0.37
Sobrevalorada
22302.27
Infravalorada
-20696.50

Precio/ventas previsto

Infravalorado
Media 5A P/S
0.99
P/S actual
0.07
Sobrevalorada
1.65
Infravalorada
0.33

Escenarios de precio de Alphio AI para DCGO

Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

A

Alcista

Alcista · 25%DCGO

$1.06

Precio del escenario

B

Base

Base · 50%DCGO

$0.91

Precio del escenario

B

Bajista

Bajista · 25%DCGO

$0.90

Precio del escenario

Cronología de eventos

2026-08-18 (ET)

16:30:00

Major Averages Decline as Bond Yields Surge

12:00:00

Major Averages Decline as Bond Yields Surge

2026-06-03 (ET)

07:40:00

DocGo Subsidiary Launches Mobile Phlebotomy Services in Southern Florida

2026-05-11 (ET)

16:10:00

DocGo Q1 Revenue $75.6M, Exceeds Consensus

2026-03-16 (ET)

16:20:00

DocGo Q4 Revenue at $74.9M, Exceeds Expectations

Noticias

Preguntas frecuentes sobre DCGO, respondidas por Alphio AI

DocGo Inc. is a mobile healthcare services company that uses dispatch and communication technology to help provide mobile, in-person medical treatment directly to patients in the comfort of their homes, workplaces and other non-traditional locations and healthcare transportation in major metropolitan cities in the United States and the United Kingdom. The Company’s offerings also include mobile phlebotomy lab services, which is engaged in addressing critical gaps in diagnostic care for underserved populations. The Mobile Health Services include a variety of healthcare services performed at homes, offices and other locations and event services, such as on-site healthcare support at sporting events and concerts. The Transportation Services encompass both emergency response and non-emergency transport services. Non-emergency transport services include ambulance transports and wheelchair transports. It operates in the Healthcare sector (SERVICES-HEALTH SERVICES industry).

DocGo Inc. is not a good buy right now. The current price is $0.2474, and the company has reported significant losses, with a net income loss of $15.82 million in Q2 2026, worsening from a $11.16 million loss last year. The RSI is at 41.90, indicating a lack of momentum for a potential upward trend. Additionally, the stock is down 72.14% year-to-date, reflecting ongoing financial struggles and market skepticism.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Artículos relacionados

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar